Results 271 to 280 of about 236,225 (308)

Trojan Horse Strategy: How Biomimetic Nanomedicine Remodels the Tumor Microenvironment

open access: yesAdvanced Science, EarlyView.
This review focuses on biomimetic nanomedicines for tumor microenvironment (TME) remodeling, covering their diverse biomimetic types, design principles, and mechanisms of immune cell reprogramming and reversal of immunosuppressive microenvironments, with particular emphasis on their application in synergistic immunotherapy.
Wanrong Wang   +7 more
wiley   +1 more source

Results of Response-Guided Therapy with Pegylated Interferon Alpha 2a in Chronic Hepatitis B and D. [PDF]

open access: yesTrop Med Infect Dis
Gherlan GS   +8 more
europepmc   +1 more source

Immunomodulatory Fibrous Scaffold with Dual Enzyme‐Mimic Activities Prevents Postsurgical Tumor Recurrence

open access: yesAdvanced Science, EarlyView.
A MnOx nanozyme‐functionalized electrospun fibrous scaffold is developed for postoperative therapy by leveraging its intrinsic physicochemical and immunomodulatory properties. Integrating POD‐ and CAT‐like activities, the scaffold induces immunogenic cell death, alleviates hypoxia, and reverses immunosuppression, while simultaneously recruiting and ...
Xiaoyi Zhao   +9 more
wiley   +1 more source

CD3ɛ Nanobody‐Engineered Extracellular Vesicles Driving In Vivo Generation of BiTE‐Secreting CAR‐Ts for Solid Tumor Therapy With Memory Response and Minimal Immunogenicity

open access: yesAdvanced Science, EarlyView.
HEK‐293T‐derived CD3ε Nb‐engineered EVs to generate dual‐targeting CAR‐T cells directly in vivo. These EVs selectively deliver CAR.BiTE transgenes into T cells and reprogramed to HLA‐G/PD‐L1‐targeting effector cells with enhanced memory and persistence.
Shi‐Wei Huang   +27 more
wiley   +1 more source

Intralesional interferon alpha-2b as a novel treatment for periocular squamous cell carcinoma in horses. [PDF]

open access: yesPLoS One
Martabano BB   +6 more
europepmc   +1 more source

Cellular Identity Crisis: RD3 Loss Fuels Plasticity and Immune Silence in Progressive Neuroblastoma

open access: yesAdvanced Science, EarlyView.
Researchers discovered that therapy‐induced loss of RD3 protein in neuroblastoma triggers a dangerous shift: cancer cells become more stem‐like, invasive, and resistant to treatment while evading immune detection. RD3 loss suppresses antigen presentation and boosts immune checkpoints, creating an immune‐silent environment.
Poorvi Subramanian   +7 more
wiley   +1 more source

ORIGINAL PAPER
Combined interferon-alpha-2b and ribavirin therapy in patients with recurring chronic hepatitis C (genotype 1) following liver transplantation in Hungary

open access: green, 2005
Gabriella Lengyel   +11 more
openalex   +1 more source

Home - About - Disclaimer - Privacy